Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drugs may offer early liver protection, study suggests

NCT ID NCT07701005

Completed Knowledge-focused Sponsor: Goztepe Prof Dr Suleyman Yalcın City Hospital Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study looks at whether two popular weight-loss medications, semaglutide and tirzepatide, can improve early signs of liver damage in people with overweight or obesity. Researchers measured changes in liver health markers after at least 12 weeks of treatment in 154 adults. The goal is to see if these drugs might help prevent fatty liver disease and related metabolic problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide or tirzepatide, injected weekly
What this could lead to
If successful, this study could show that these medications improve liver health in people with overweight or obesity, potentially reducing the risk of liver disease.
What could go wrong
This is a small, retrospective study from a single center, so results may not apply to everyone. It only looks at early changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease Insulin Resistance metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Overweight visceral steatosis, congenital

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSULIN RESISTANCE METABOLIC LIVER INJURY OBESITY OVERWEIGHT STEATOSIS OF LIVER

Contacts and locations

Locations

  • Facility: Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.